Intravesical Drug Delivery Systems for Bladder Cancer Therapy

Intravesical drug delivery systems have become integral to the management of bladder cancer, particularly non-muscle-invasive disease, by enabling high local concentrations of cytotoxic or immunotherapeutic agents within the urinary bladder. Traditional instillation methods suffer from rapid dilution and excretion by urine, as well as limited penetration across the urothelium. To overcome these challenges, researchers have developed a range of formulations and devices designed to adhere to the bladder mucosa, to form in situ gels, or to expand as indwelling implants. Nanoparticles, nanogels and lipid-based carriers enhance mucoadhesion and tissue permeation, while thermosensitive and ion-responsive polymers exploit physiological triggers to transition from liquid to gel on administration. Advancements in shape-memory materials and 4D-printed scaffolds offer further potential for prolonged retention and controlled drug release. Together, these approaches aim to reduce recurrence rates, limit systemic toxicity and improve patient comfort by reducing the frequency of catheterisation. The global burden of bladder cancer and the need for repeat interventions underscore the practical importance of these innovations.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Intravesical Drug Delivery Systems for Bladder Cancer Therapy publication trend

The graph below shows the total number of articles in intravesical drug delivery systems for bladder cancer therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Mucoadhesion: The property of a material to adhere to mucosal tissues, prolonging residence time and improving local drug concentration.

In situ gelling: A formulation that undergoes a sol-to-gel transition upon exposure to physiological conditions, such as temperature or pH, to retain drugs at the target site.

Urothelium: The specialised epithelial lining of the urinary bladder that acts as a barrier to fluid and solute passage.

Nanoparticle: A substance or device in the size range 1–1000 nm used to encapsulate and deliver therapeutic agents with controlled release properties.

Intravesical instillation: The direct administration of a liquid therapeutic formulation into the bladder via catheterisation for localised treatment.

References

1. Thiolated Mesoporous Silica Nanoparticles as an Immunoadjuvant to Enhance Efficacy of Intravesical Chemotherapy for Bladder Cancer. Advanced Science (2023).
2. Quercetin Loaded Cationic Solid Lipid Nanoparticles in a Mucoadhesive In Situ Gel—A Novel Intravesical Therapy Tackling Bladder Cancer. Pharmaceutics (2022).
3. Intravesical drug delivery approaches for improved therapy of urinary bladder diseases. International Journal of Pharmaceutics X (2021).